Post-production protein stability: trouble beyond the cell factory

Microbial Cell Factories

Commentary

José Luis Corchero¹  Esther Vazquez²  Antonio Villaverde² 

[1] CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN, Bellaterra, 08193, Barcelona, Spain;Institute for Biotechnology and Biomedicine, Universitat Autònoma de Barcelona, Bellaterra, 08193, Barcelona, Spain;Department of Genetics and Microbiology, Universitat Autònoma de Barcelona, Bellaterra, 08193, Barcelona, Spain;Institute for Biotechnology and Biomedicine, Universitat Autònoma de Barcelona, Bellaterra, 08193, Barcelona, Spain;Department of Genetics and Microbiology, Universitat Autònoma de Barcelona, Bellaterra, 08193, Barcelona, Spain;CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN, Bellaterra, 08193, Barcelona, Spain;

关键词: Protein Engineering;    Recombinant Protein Production;    Protein Drug;    Protein Quality Control;    Protein Version;   

DOI  :  10.1186/1475-2859-10-60

 received in 2011-07-25, accepted in 2011-08-01,  发布年份 2011

来源: Springer

【 摘 要 】

Being protein function a conformation-dependent issue, avoiding aggregation during production is a major challenge in biotechnological processes, what is often successfully addressed by convenient upstream, midstream or downstream approaches. Even when obtained in soluble forms, proteins tend to aggregate, especially if stored and manipulated at high concentrations, as is the case of protein drugs for human therapy. Post-production protein aggregation is then a major concern in the pharmaceutical industry, as protein stability, pharmacokinetics, bioavailability, immunogenicity and side effects are largely dependent on the extent of aggregates formation. Apart from acting at the formulation level, the recombinant nature of protein drugs allows intervening at upstream stages through protein engineering, to produce analogue protein versions with higher stability and enhanced therapeutic values.

【 授权许可】

Unknown   
© Vazquez et al; licensee BioMed Central Ltd. 2011. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.